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&s.tract The degradation of tenascin purified from human melanoma cells was examined by treatment with matrix metalloproteinases (MMPs) 
md serine proteinases. Among eight different types of proteinases xamined, MMP-1, -3, and -7, cathepsin G and leukocyte lastase could digest 
enascin, but MMP-2, MMP-9 and thrombin did not. This suggests that tenascin may be readily catabolized by extracellular matrix-degrading 
lroteinases found in the pathophysiological conditions. 
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I. Introduction 
Tenascin is a hexameric protein of more than 1,000 kDa, 
:ach subunit of which is in the range of 200-300 kDa depending 
m the species. It is identified in a wide range of species includ- 
ng chickens, rats, mice, cows, pigs and human, and variously 
,eferred to as tenascin, hexabrachion, cytotactin, myotendi- 
IOUS antigen, J 1, glial-mesenchymal extracellular matrix pro- 
ein, or neurotactin [1,2]. Tenascin is known to participate in 
:ell adhesion and repulsion, guidance along cell migration- 
)athways, the shedding of epithelial cells, the demarcation of 
issue boundaries, the stimulation of cell growth, and hemag- 
ilutination [2,3]. Localization studies have shown that tenascin 
s transiently observed in connective tissues during embryo- 
genesis and in some adult tissues under the pathophysiological 
:onditions such as malignant tumors [l]. During fetal lung 
levelopment enascin accumulated at the epithelial-mesenchy- 
nal interface is quickly degraded after decrease in the mRNA 
:xpression [4]. However, no information is so far available for 
he proteinases which can degrade tenascin. 
We report here that tenascin is susceptible to proteolysis by 
natrix metalloproteinases (MMPs) including MMP-1 (tissue 
:ollagenase; EC 3.4.24.7), MMP-3 (stromelysin 1; EC 3.4.24.17) 
md MMP-7 (matrilysin; EC 3.4.24.23), cathepsin G (EC 
3.4.21.20) and leukocyte elastase (EC 3.4.21.37). 
!. Materials and methods 
?.I. Materials 
Materials were obtained as follows: Brij 35, diisopropyl fluoro- 
lhosphate (DIFP), leukocyte elastase and thrombin (bovine) (EC 
1.4.21.5) from Sigma Chemical Co.; acrylamide, ethylenediamine- 
etraacetic acid (EDTA) and sodium dodecyl sulfate from Wako 
Them., Japan; 4-aminophenylmercuric a etate (APMA) from Aldrich 
lhemical Co.; Sephadex G-10 from Pharmacia Fine Chemicals; cathep- 
YZorresponding author. Fax: (81) (762) 34-4228. 
4bbreviations: MMP, matrix metalloproteinase; DIFP, diisopropyl 
luorophosphate; EDTA, ethylenediaminetetraacetic acid; APMA, 
t-aminophenylmercuric a etate; SDS-PAGE, sodium dodecyl sulfate- 
,olyacrylamide gel electrophoresis. 
sin G from ICN Biochemicals; Na’*‘I (549 MBq/pg) from Amersham. 
The zymogens of MMP-I, -2 (gelatinase A; EC 3.4.24.24) and -3 were 
purified from the culture medium of rheumatoid synovial fibroblasts 
as previously described [5-71. The zymogens of MMP-7 and -9 (gelati- 
nase B; EC 3.4.24.35) were also purified from the culture media of 
CaR-I rectal carcinoma cells (Imai et al., manuscript submitted) and 
HT-1080 fibrosarcoma cells [8], respectively. These proenzymes were 
fully activated by incubation with APMA as described previously [&9]. 
2.2. PuriJication and radioiodination of tenascin 
Human tenascin was purified from melanoma cell conditioned me- 
dium as previously reported [lo]. Purified tenascin was iodinated ac- 
cording to the method of Fraker and Speck [ll] and free ‘*‘I was 
removed from the sample by spin column of Sephadex G-10 equili- 
brated with 50 mM Tris-HCl, pH 7.5,0.15 M NaCI, 0.05% Brij 35 and 
0.02% NaN, as previously described [7]. 
2.3. Digestion of tenascin by endopeptidases 
Digestion of a mixture of ‘2SI-labelled and non-labelled tenascin was 
carried out by incubation with the proteinases in an enzyme-to-sub- 
strate ratio of 1:25 in 50 mM Tris-HCI, pH 7.5, containing 0.15 M 
NaCl, 10 mM CaCl,, 0.05% Brij 35 and 0.02% NaN, at 37°C. For the 
digestion with MMP-2 and MMP-9 the enzyme-to-substrate ratio was 
increased up to 1 : 1. The reactions were terminated with 20 mM EDTA 
and 2 mM DIFP for activities of MMPs and serine proteinases, respec- 
tively. The digestion products were analyzed by sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE) (5% acrylamide) 
under the non-reducing or reducing conditions, and the gels were au- 
toradiographed. 
3. Results 
When tenascin purified from the human melanoma cells was 
analyzed by SDS-PAGE without reduction, two aggregated 
protein bands with very high molecular weight were identified 
in the upper gel and at the top of the lower gel, which may 
correspond to haxamer and trimer of the subunit, as previously 
noted [12] (Fig. 1A). Under the reducing conditions, they were 
migrated as a major protein band of -250 kDa (Fig. 1B). Incu- 
bation of the substrate with MMP-1, -2, -3, -7 or -9 and subse- 
quent analysis of the products by SDS-PAGE showed that 
MMP-1, -3 and -7 degrade tenascin (Figs. 1 and 2). MMP-1 and 
MMP-3 had similar actions on tenascin and digested it into 
major fragments of 210, 120 and 100 kDa under reduction (Fig. 
1B). Under the non-reducing conditions, the huge aggregated 
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form observed in the upper gel appeared to be processed to two 
fragments (Fig. 1A). Time course study of the digestion by 
MMP-1 and MMP-3 showed that the conversion of tenascin 
to the fragment of 210 kDa is initiated at 4 h incubation and 
completed after 12 h incubation without further degradation of 
the product by longer incubation up to 24 h (data not shown). 
On the other hand, MMP-7 degraded tenascin into several 
fragments with less than 190 kDa under reduction and the 
aggregated form found under non-reduction disappeared (Fig. 
2A and B). In contrast to the actions of these MMPs, tenascin 
was resistant o MMP-2 or MMP-9 (Fig. 1A and B). This was 
the case even when the substrate was incubated with each MMP 
in a 1:l enzyme-to-substrate ratio (data not shown). 
Tenascin was extremely susceptible to cathepsin G and leu- 
kocyte elastase (Fig. 2A and B), whereas no degradation was 
observed with thrombin under the similar conditions (data not 
shown). These two serine proteinases digested the protein into 
multiple small fragments under both non-reducing and reduc- 
ing conditions (Fig. 2A and B). 
4. Discussion 
The present study demonstrates for the first time that tenas- 
tin is degraded by MMP-1, MMP-3, MMP-7, cathepsin G and 
leukocyte elastase. The degradation by MMP-1 and MMP-3 
seemed to be limited digestion, producing similar large frag- 
ments under reduction. On the other hand, tenascin was most 
susceptible to digestion by MMP-7 among MMP-1, -2, -3, -7 
and -9. Obviously, MMP-7 degrades tenascin at multiple sites 
because of the many fragments generated by the incubation 
with MMP-7. Although MMP-1 is an enzyme active basically 
on the fibrillar collagens such as types I, II and III [13], the 
present result adds tenascin to the list of the substrates. The 
substrate specificity of MMP-3 and MMP-7 is reported to be 
similar [13]. This is the case with tenascin although the specific 
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Fig. 1. SDS-PAGE of the reaction products of ‘Wabelled tenascin 
generated by incubation with MMP-I, -2, -3 and -9. The substrate 
(1 pug) was incubated with MMP-1 (lane 2), MMP-2 (lane 3), MMP-3 
(lane 4) or MMP-9 (lane 5) (40 ng each) for 24 h at 37°C. The digestion 
products were subjected to SDS-PAGE (5% acrylamide) under non- 
reduction (A) or reduction (B) and the gels were autoradiographed. 
Lane 1 is the control sample incubated with buffer alone for 24 h at 
37°C. 
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Fig. 2. SDS-PAGE of the degradation products of tenascin with MMP- 
7, cathepsin G and leukocyte lastase. The substrate was incubated with 
MMP-7 (lane 2), cathepsin G (lane 3) or leukocyte lastase (lane 4) and 
the reaction products were analyzed by SDS-PAGE under non-reduc- 
tion (A) or reduction (B) as described in Fig. 1. Lane 1 is the control 
sample incubated with buffer alone. 
activity of MMP-7 seems to be greater than that of MMP-3. 
The present data that tenascin is completely resistant to the 
action of MMP-2 and MMP-9 suggest hat these gelatinases 
play limitted or no role in the turnover in vivo. Cathepsin G 
and leukocyte elastase most effectively digested tenascin into 
small peptides. Because both serine proteinases are derived 
from polymorphonuclear leukocytes [14], their role in the te- 
nascin degradation may be important in the tissues with suppu- 
rative inflammation. 
Tenascin is a unique protein, which is transiently observed 
in the tissues during the embryogenesis and in some adult tis- 
sues such as the endometrium [15], the healing wounds [ 161 and 
the tumor stroma [l]. Although the tissue- and time-specific 
localization may be ascribed to the transient expression of the 
tenascin gene, it can also be explained by enhanced degradation 
of tenascin by proteinases in the tissues. In fact, tenascin-de- 
grading MMPs are known to be expressed in these tissues; 
MMP-1, -3 and -7 in the endometrium [17,18], MMP-1 and -3 
in the healing wounds [19,20], and many types of MMPs includ- 
ing MMP-1, -3 and -7 in the tumors [21]. Since the tissues are 
frequently infiltrated by leukocytes, both groups of the MMPs 
and serine proteinases may be implicated in the normal turno- 
ver and/or pathological degradation of tenascin in vivo. 
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